Targeted therapy is the standard treatment of patients with metastatic cancer of the kidney. The best current therapies target the tumour vasculature thereby blocking the access of the tumour to nutrients and limiting possibility of spreading to distant parts of the body.

Fig. 1. Probability of relapse was similar in patients who coninued therapy and those who did not after reaching complete response.

Kidney cancer that has already spread and formed metastases is considered incurable. However, a minor part of patients will have excellent response to targeted therapies and will experience complete response – disappearance of all tumour lesions. We believe that this does not, unfortunately, mean cure because the tumour will come back (relapse) in almost all of them after certain time. Nevertheless, interruption of treatment may be possible and is often done in these patients to enable them a period of rest from side effects of therapy.

According to this registry-based analysis, patients with metastatic renal cancer with no signs of disease (complete response) after treatment with targeted agents experience excellent long-term survival even if the treatment does not continue beyond the date of complete response.

Of 2803 patients with data on targeted therapy in our national registry, 100 patients achieved complete response. These patients experienced excellent survival and 80% were still alive 5 years after the start of therapy. This is much better than average patients treated for metastatic kidney cancer. Importantly, if the treatment was discontinued while the patients were still in complete response, the survival was not adversely affected.  This is a retrospective study with some limitations but the results are encouraging for those patients who have complete response and want to spend some time off treatment, and their physicians.

Tomas Buchler
Department of Oncology, First Faculty of Medicine
Charles University and Thomayer Hospital
Prague, Czech Republic

Publication

Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis.
Buchler T, Bortlicek Z, Poprach A, Pavlik T, Veskrnova V, Honzirkova M, Zemanova M, Fiala O, Kubackova K, Slaby O, Svoboda M, Vyzula R, Dusek L, Melichar B; Czech Renal Cancer Cooperative Group.
Eur Urol. 2015 Dec 30

Read offline:     

Related Articles:

	What treatment is really medically and economically… Currently, direct-acting agent (DAA) therapies have high efficacy and safety and are the main strategy to eliminate hepatitis C virus (HCV) worldwide. Some DAA therapies are also effective for HCV-infected…
	Clinically utilized nalfurafine combined with naltrexone… Alcohol addiction poses massive public health costs [~15 million adult alcoholics with economic cost > $200 billion/year in the US]. Pharmacological studies in rodents have demonstrated that kappa-opioid receptor (KOR)…
	Excess nutrients cause environmental deterioration in the… The introduction of excess nutrients (i.e., nitrogen and phosphorus) to coastal areas can have a series of impacts. One of the most common is eutrophication—the enrichment of water with surplus…
	Macrophage-myofibroblast transition: a novel target for… Kidney is one of the major organs in our body for detoxification. Its failure is an important cause of patient mortality that serves as a primary disease and a lethal…
	RNA signature in brain lesions of damage or repair in… We explored mechanistic signatures of different lesion types in the brain of patients with progressive MS: normal-appearing white matter (NAWM), active, chronic active (slowly expanding), inactive and repairing (remyelinating) lesions…
	The complex regulation and functional significance of size… Across animals, variation in body size is often influenced by environmental conditions and is considered to have adaptive value. In bees, in which many species show various degrees of sociality,…